Mineralys Therapeutics, Ebit Over Time
| MLYS Stock | 13.11 0.59 4.71% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Mineralys Therapeutics, Performance and Mineralys Therapeutics, Correlation. Mineralys |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mineralys Therapeutics,. If investors know Mineralys will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mineralys Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.31) | Return On Assets (0.39) | Return On Equity (0.61) |
The market value of Mineralys Therapeutics, is measured differently than its book value, which is the value of Mineralys that is recorded on the company's balance sheet. Investors also form their own opinion of Mineralys Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Mineralys Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mineralys Therapeutics,'s market value can be influenced by many factors that don't directly affect Mineralys Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mineralys Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Mineralys Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mineralys Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Ebit Analysis
Compare Mineralys Therapeutics, and related stocks such as Cue Biopharma, Tff Pharmaceuticals, and Eliem Therapeutics Ebit Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CUE | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (7.7 M) | (23.2 M) | (38.7 M) | (36.8 M) | (45 M) | (43.7 M) | (52.3 M) | (49.5 M) | (52 M) |
| TFFP | (370.4 K) | (370.4 K) | (370.4 K) | (370.4 K) | (370.4 K) | (370.4 K) | (370.4 K) | (178.6 K) | (3.9 M) | (12 M) | (18.7 M) | (31 M) | (31.8 M) | (21.2 M) | (22.3 M) |
| INBX | (19.7 M) | (19.7 M) | (19.7 M) | (19.7 M) | (19.7 M) | (19.7 M) | (19.7 M) | (19.7 M) | (29.4 M) | (43.7 M) | (67.4 M) | (76.6 M) | (129.1 M) | (207.9 M) | (197.5 M) |
| MOLN | 7.3 M | 7.3 M | 7.3 M | 7.3 M | 2.2 M | (1.9 M) | (19.2 M) | (25.2 M) | (37.2 M) | (36.7 M) | (62.5 M) | (63.4 M) | 118.5 M | (62 M) | (58.9 M) |
Mineralys Therapeutics, and related stocks such as Cue Biopharma, Tff Pharmaceuticals, and Eliem Therapeutics Ebit description
My Equities
My Current Equities and Potential Positions
| Mineralys Therapeutics, Common | MLYS |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Pennsylvania; U.S.A |
| Exchange | NASDAQ Exchange |
null 13.11
Additional Tools for Mineralys Stock Analysis
When running Mineralys Therapeutics,'s price analysis, check to measure Mineralys Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mineralys Therapeutics, is operating at the current time. Most of Mineralys Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Mineralys Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mineralys Therapeutics,'s price. Additionally, you may evaluate how the addition of Mineralys Therapeutics, to your portfolios can decrease your overall portfolio volatility.